Michael Gibney

4 days ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. Treatment options and survival rates for patients with the world’s deadliest cancers have skyrocketed over the course of decades with much credit to the pharma and biotech industry. But how do drugmakers reach the critical next step in innovation? That’s not a question easily answered by even the top oncology companies as they seek opportunities for game-changing treatments in a sea of incremental efforts.

1 week ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. The journey to new Alzheimer’s disease drugs has been long, grueling and littered with pitfalls. Through failed trials and regulatory scrutiny, several new drugs promise concrete — albeit incremental — treatment for the devastating disease.

2 weeks ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. When the CEO of a major pharmaceutical company steps down, the transition often comes at a time of reinvention. While many factors play into a decision to shuffle the C-suite, Big Pharma has seen turnover in the last few years as a result of looming patent cliffs, shifting competitive landscapes or poor financial performance.

3 weeks ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. Welcome to First 90 Days, a series dedicated to examining how pharma executives and other leaders are planning for success in their new roles. Today, we’re speaking to Amy Parison, CFO at Editas Medicine, which is undergoing a shift in focus to in vivo therapies and navigating the many challenges of the gene editing space. Gene editing biotech Editas Medicine is no stranger to the drug development pivot.

3 weeks ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. All the scientific breakthroughs and billions of dollars spent on medical innovation don’t mean a thing unless patients have access to new treatments. So when pharmaceutical companies develop cutting-edge oncology therapies that promise to dramatically alter the once-grim prospects of a cancer diagnosis, community oncology networks rely on drugmakers to build a bridge between innovation and clinical use.